On May 21, Sino Biopharmaceutical (1177.HK) and Boehringer Ingelheim jointly announced that Hernexeos® (generic name in Chinese: zongertinib tablets, generic name in English: zongertinib), which they are co-promoting in mainland China, has been approved by the China National Medical Products Administration (NMPA).

Recently, the world-renowned business magazine Fortune released the "2026 China Environmental, Social, and Governance (ESG) Impact List".

Recently, for Kylo-11 (LPA-siRNA), independently developed by Hygieia Pharma, a wholly-owned subsidiary of Sino Biopharm (1177.HK), the enrollment of all subjects in the China region for a Phase II clinical trial has been successfully completed.

On May 14, the 6th CICC Healthcare Industry Summit 2026 was held in Shanghai. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical (1177.HK), attended and delivered a speech, providing a clear answer for achieving a global breakthrough through a differentiated M&A strategy for local Chinese pharmaceutical companies, combined with a leading advantage across the entire value chain.

On May 12, the inaugural Hong Kong Embodied AI Industry Summit, co-initiated by the Hong Kong Federation of Overseas Chinese Associations and AgileX Robotics, opened in Hong Kong. John Lee Ka-chiu, Chief Executive of the Hong Kong Special Administrative Region; Frederick Ma Si-hang, Chairman of the Hong Kong Trade Development Council; Cheng Cheung Ling, President of Chia Tai Pharmaceutical Group and President of the Hong Kong Federation of Overseas Chinese Associations, attended the event and delivered speeches.

On the morning of May 11, the 6th Asia Summit on Global Health (ASGH), co-hosted by the HKSAR Government and the Hong Kong Trade Development Council, opened at the Hong Kong Convention and Exhibition Centre.

On May 11, Sino Biopharm (1177.HK) officially announced that its core enterprise, Chia Tai Tianqing, has entered into an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the marketing process of the first-in-class (FIC) new drug Bepirovirsen in China. Earlier this year, a marketing application for Bepirovirsen was submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and was included in the priority review list.

Recently, the first patient was enrolled and dosed in a Phase III registrational clinical trial at the General Hospital of Pingmei Shenma Medical Group. The trial is for Cafelkibart (LM-108, a CCR8 monoclonal antibody), a Class 1 innovative drug independently developed by LaNova Medicines, a wholly-owned subsidiary of Sino Biopharm (1177.HK).

When a malignant tumor invades the serous layer of the thoracic or abdominal cavity, it can lead to abnormal fluid accumulation, causing dyspnoea, abdominal distension, anorexia, etc., which severely affect the patient's quality of life.

Recently, Chia Tai Tianqing, the core enterprise of Sino Biopharm (1177.HK), received a formal notification from the European Medicines Agency (EMA) that the company has successfully passed the comprehensive review of EU GMP compliance inspection and has been awarded the EU GMP certificate for human medicinal products. Since first passing the EMA inspection in 2014, Chia Tai Tianqing has passed the EU GMP certification to a high standard five consecutive times, with multiple products entering the EU market to benefit patients worldwide.